Phaseline

Companies › Prana Therapies

Prana Therapies: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 1; Immunology, Respiratory; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PRA-216–Phase 2Chronic Obstructive Pulmonary Disease (COPD); Atopic Dermatitis (AD); Mild to Moderate AsthmaJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07245368PRA-216Phase 1Mild to Moderate AsthmaRespiratoryJan 2027
NCT07730281PRA-216Phase 2Chronic Obstructive Pulmonary Disease (COPD)RespiratoryJun 2027
NCT07810777PRA-216Phase 2Atopic Dermatitis (AD)ImmunologySep 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Enveda Therapeutics Cumberland Pharmaceuticals ReAlta Life Sciences Avalyn Pharma Toll Biotech Co. Ltd. (Beijing)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.